Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recurrent Clostridium difficile infection (CDI) with poor response to standard antimicrobial therapy is a growing medical concern. We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric tube (NGT) administration. METHODS: Healthy volunteer donors were screened and a frozen fecal suspension was generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea without relapse after 8 weeks. The secondary endpoint was self-reported health score using standardized questionnaires. RESULTS: A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median of 4 (range, 2-16) relapses prior to study enrollment, with 5 (range, 3-15) antibiotic treatment failures. Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated, with 4 obtaining cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from a median of 7 (interquartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion. Self-ranked health score improved significantly, from a median of 4 (IQR, 2-6) before transplant to 8 (IQR, 5-9) after transplant. No serious or unexpected adverse events occurred. CONCLUSIONS: In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI. NGT administration appears to be as effective as colonoscopic administration. CLINICAL TRIALS REGISTRATION: NCT01704937.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a pilot open-label randomized trial, frozen FMT by nasogastric tube appeared to be as effective as colonoscopic administration in resolving CDIassociated diarrhea. 126”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [126]
In the citing paper
“Youngster et al. conducted a randomized pilot study comparing upper and lower GI routes of FMT, and the report found a non-significant difference in cure rate between the two different administration methods.67”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [67]
In the citing paper
“FMT has been examined in both young and old, patients with limited comorbidities as well as those considered to be immunocompromised,43 and the procedure has been shown to be safe, well-tolerated, and effective.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“Furthermore, flares of FMT in patients with both UC and CD have been described,43, 75, 76 raising important questions around safety and the potential to worsen disease in some patients.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“These include complications of endoscopy, such as perforation and bleeding, and side effects related to sedation, such as aspiration43.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839 · cited 1×
“DNA was extracted and the V4 region of the 16S gene was sequenced using an Illumina MiSeq (Illumina, San Diego, CA) as described previously [30].”
MethodDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569 · cited 1×
“0 [26] approved by the FDA and institutional review board (IRB).”
BackgroundFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585 · cited 1×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 1×
“The emergence of a virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of treatment failure [9,10].”
BackgroundClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 1×
“In the United States the incidence of CDI has tripled over the last 15 years [3].”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 1×
“Failure to reconstitute normal flora was shown to be a factor in severe, recurrent, and prolonged illness [13].”
BackgroundTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 1×
“5 guidelines [26] by a relapse of CDI after having at least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic, OR, at least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.”
BackgroundSelf-citationKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 1×
“Another inhibiting factor is the fact that the available data are mostly based on retrospective case series and include only a single randomized trial [21,24,25] to date, making practitioners cautious about adopting FMT as a viable treatment alternative.”
BackgroundHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 1×
“The work of Hamilton and Khoruts [28] was used as a guide for fecal manipulation, with the exception that all processes were carried out under ambient air, not nitrogen.”
Method
Research works printed but not linked: 1
- 2013, Clostridium difficile infection in children, JAMA Pediatr, 167, 567, 10.1001/jamapediatrics.2013.441 · DOI · Paper page
Cited by
Items 101–200 of 500
Ericsson, A. C., Personett, A. R., Turner, G., Dorfmeyer, R. A., & Franklin, C. L. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00196 · Cited by 86
“FMT has gained well-deserved attention in human medicine as an effective means of treating antibiotic-induced overgrowth of Clostridium difficile, with an estimated therapeutic efficacy of 80–90% (Kassam et al., 2013; Kelly et al., 2014; Youngster et al., 2014a).”
BackgroundCryopreservation of artificial gut microbiota produced with in vitro fermentation technology
Bircher, L., Schwab, C., Geirnaert, A., & Lacroix, C. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12844 · Cited by 83
“Furthermore, only minor viability drops in the tested cultivable anaerobes over 6 months of frozen storage were reported (van Nood et al., 2013; Youngster et al., 2014; Costello et al., 2015; Satokari et al., 2015).”
BackgroundBloom, P. P., Donlan, J., Soto, M. T., Daidone, M., Hohmann, E. L., & Chung, R. T. (2022) · Hepatology Communications · doi:10.1002/hep4.1950 · Cited by 82
“FMT donors were healthy adults with normal body mass index who were selected through a previously published rigorous screening process.[12,13] FMT capsules were generated using established protocols and approved by the local institutional review board and the FDA.”
MethodSelf-citationKronman, M. P., Nielson, H. J., Adler, A. L., Giefer, M. J., Wahbeh, G., Singh, N., Zerr, D. M., & Suskind, D. L. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000545 · Cited by 76
“ecal microbiota transplantation (FMT) has been shown to be an colonoscopy and nasogastric (NG) tube appears equally efficacious (7).”
BackgroundFecal microbiota transplantation for the treatment of Clostridium difficile infection
Rao, K., & Safdar, N. (2016) · Journal of Hospital Medicine · doi:10.1002/jhm.2449 · Cited by 70
“conducted a pilot RCT with 10 patients in each group, where patients were randomized to receive FMT via either colonoscopy or nasogastric tube from a frozen fecal suspension, and no difference in efficacy was seen between administration routes, with an overall cure rate of 90%.(40) Subsequently, Youngster et al.”
MethodZikou, E., Koliaki, C. C., & Makrilakis, K. (2024) · Biomedicines · doi:10.3390/biomedicines12081871 · Cited by 81
“When the screening of the candidate donor is completed, the fecal sample is obtained and the preparation of the fecal transplant begins, either for delivery directly to the recipient or for cryopreservation [62,63].”
BackgroundMullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.07.037 · Cited by 79
“Minor subsequent adverse events have included a range of GI side effects including self-limiting abdominal discomfort [14,17,62,80], nausea [14,54,75], flatulence [14,16,17,46,47, 54,62], self-limiting irregular bowel movements [46], C.”
BackgroundInfluentialEncapsulated Fecal Microbiota Transplantation: Development, Efficacy, and Clinical Application
Halaweish, H., Boatman, S. M., & Staley, C. M. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.826114 · Cited by 78
Carlucci, C., Petrof, E. O., & Allen-Vercoe, E. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.029 · Cited by 77
“Recent studies have demonstrated effectiveness of FMT for clinical cure of rCDI around 90% (Agrawal et al., 2016; Kelly et al., 2016; van Nood et al., 2013; Youngster et al., 2016, 2014).”
BackgroundStool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank
Chen, J., Zaman, A., Ramakrishna, B., OpenBiome Team, & Olesen, S. W. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.622949 · Cited by 77
Bella, S. D., Gouliouris, T., & Petrosillo, N. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.01.011 · Cited by 77
Subtle Microbiome Manipulation Using Probiotics Reduces Antibiotic-Associated Mortality in Fish
Schmidt, V. T., Marta Gómez-chiarri, G., Roy, C., Smith, K. F., & Amaral‐Zettler, L. (2017) · mSystems · doi:10.1128/msystems.00133-17 · Cited by 75
“and drastically reduced fecal microbiome diversity (9, 10).”
Vemuri, R. C., Gundamaraju, R., Shinde, T., & Eri, R. (2017) · Beneficial Microbes · doi:10.3920/bm2016.0115 · Cited by 66
Tang, G., Yin, W., & Liu, W. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.05.007 · Cited by 72
Allegretti, J. R., Fischer, M., Sagi, S. V., Bohm, M. E., Fadda, H. M., Ranmal, S. R., Budree, S., Basit, A. W., Glettig, D. L., de la Serna, E. L., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5396-6 · Cited by 72
Self-citationKhan, M. Y., Dirweesh, A., Khurshid, T., & Siddiqui, W. J. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001243 · Cited by 61
Fecal microbiota transplantation for Crohn’s disease: a systematic review and meta-analysis
Cheng, F., Huang, Z., Wei, W., & Li, Z. (2021) · Techniques in Coloproctology · doi:10.1007/s10151-020-02395-3 · Cited by 67
“Several studies reported that FMT success was not affected by the route of administration [34, 35].”
BackgroundLagier, J., Delord, M., Million, M., Parola, P., Stein, A., Brouqui, P., & Raoult, D. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2394-x · Cited by 66
Kwak, S., Choi, J., Hink, T., Reske, K. A., Blount, K., Jones, C. R., Bost, M. H., Sun, X., Burnham, C. D., Dubberke, E. R., et al. (2020) · Microbiome · doi:10.1186/s40168-020-00907-9 · Cited by 66
Chin, S. M., Sauk, J. S., Mahabamunuge, J., Kaplan, J. L., Hohmann, E. L., & Khalili, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.11.028 · Cited by 65
“Information on donor selection, stool preparation, and transplantation using colonoscopy, nasogastric/duodenal tube, or frozen capsules has previously been reported.(2) Briefly, patients undergoing FMT received follow-up telephone calls at 1–3 days, 2 weeks, 8 weeks, and 6 months to collect information on potential si…”
BackgroundMethodSelf-citationAllegretti, J. R., Kassam, Z., Osman, M., Budree, S., Fischer, M., & Kelly, C. R. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.05.036 · Cited by 63
The Role of Prebiotics and Probiotics in Gastrointestinal Disease
Floch, M. H. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.09.011 · Cited by 66
DeFilipp, Z. M., Hohmann, E. L., Jenq, R. R., & Chen, Y. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.10.022 · Cited by 63
Self-citationRajasingham, R., Enns, E. A., Khoruts, A., & Vaughn, B. P. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz318 · Cited by 62
MERS: Progress on the global response, remaining challenges and the way forward
Aguanno, R., IDRISSI, A. H. E., Elkholy, A. A., Embarek, P. B., Gardner, E. G., Grant, R., Mahrous, H., Malik, M. R., Pavade, G., VonDobschuetz, S., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.09.002 · Cited by 60
Yang, Z., Bu, C., Yuan, W., Shen, Z., Quan, Y., Wu, S., Zhu, C., & Wang, X. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05751-y · Cited by 60
Kearney, S. M., Gibbons, S. M., Poyet, M., Gurry, T., Bullock, K., Allegretti, J. R., Clish, C. B., & Alm, E. J. (2018) · The ISME Journal · doi:10.1038/s41396-018-0192-z · Cited by 59
“Because of this depletion in rOTUs, we expected that fecal microbiota transplant (FMT) might transfer relatively more rOTUs than other OTUs [46].”
Self-citationRao, K. K., & Higgins, P. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000793 · Cited by 59
Goldenberg, S. D., Batra, R., Beales, I., Digby-Bell, J. L., Irving, P. M., Kellingray, L., Narbad, A., & Franslem-Elumogo, N. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0189-y · Cited by 56
“One randomized study comparing upper and lower GI administration found a non-significantly higher cure rate with colonoscopy; however, this was a pilot study with only five and six patients in each arm [8].”
The Conceptual Ecology of the Human Microbiome
Morar, N., & Bohannan, B. J. M. (2019) · The Quarterly Review of Biology · doi:10.1086/703582 · Cited by 57
Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future
Panchal, P., Budree, S., Scheeler, A., Medina, G., Seng, M., Wong, W. F., Eliott, R., Mitchell, T., Kassam, Z., Allegretti, J. R., et al. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0619-8 · Cited by 57
Stripling, J., & Rodriguez, M. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.08.010 · Cited by 48
Angiogenesis, a key point in the association of gut microbiota and its metabolites with disease
Wang, Y., Bai, M., Peng, Q., Li, L., Tian, F., Guo, Y., & Jing, C. (2024) · European journal of medical research · doi:10.1186/s40001-024-02224-5 · Cited by 55
“A randomized controlled trial confirmed that encapsulated FMT is effective for recurrent Clostridium difficile infection (CDI) [278, 279].”
Reygner, J., Charrueau, C., Delannoy, J., Mayeur, C., Robert, V., Cuinat, C., Meylheuc, T., Mauras, A., Augustin, J., Nicolis, I., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1759489 · Cited by 55
“Now, frozen fecal material is widely used and several randomized controlled trials have confirmed that the use of frozenand-thawed material is non-inferior (versus fresh) in terms of cure rates for recurrent CD infection.(4,6) A few studies have reported protocols using encapsulated frozen stool allowing oral administ…”
BackgroundKelly, B. J., & Tebas, P. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.09.002 · Cited by 54
“Results from subsequent studies have supported the equivalent efficacy of frozen stool preparation.(41,42,44) Given the imperative for rigorous donor screening and the difficulty of timing donation, most institutions performing regular FMT have developed local banks of frozen stool preparations or work with outside st…”
MethodResultInfluentialKhanna, S., & Pardi, D. S. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1158097 · Cited by 53
Hecker, M. T., Obrenovich, M. E., Cadnum, J. L., Jencson, A. L., Jain, A. K., Ho, E. Y., & Donskey, C. J. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw091 · Cited by 53
Okahara, K., Ishikawa, D., Nomura, K., Ito, S., Haga, K., Takahashi, M., Shibuya, T., Osada, T., & Nagahara, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061650 · Cited by 53
“Additionally, several studies have employed volunteer donors, and there is no consensus on the selection of appropriate donors [20].”
BackgroundFecal microbiota transplantation: a novel strategy for treating Alzheimer’s disease
Xiang, W., Xiang, H., Wang, J., Jiang, Y., Pan, C., Ji, B.-J., & Zhang, A. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1281233 · Cited by 52
Merlo, G., Graves, N., Brain, D., & Connelly, L. B. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13402 · Cited by 50
The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis
Costello, M., Robinson, P. C., Benham, H., & Brown, M. A. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.08.001 · Cited by 51
Segal, J. P., Mullish, B. H., Quraishi, M. N., Iqbal, T. H., Marchesi, J. R., & Sokol, H. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820946904 · Cited by 51
Mihaljevic, J. R., Hoye, B. J., & Johnson, P. T. J. (2017) · Journal of Animal Ecology · doi:10.1111/1365-2656.12735 · Cited by 50
Baro, E., Galpérine, T., Deniès, F., Lannoy, D., Lenne, X., Odou, P., Guery, B. P., & Dervaux, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170258 · Cited by 50
Microbiota-Based Therapies for Clostridium difficile and Antibiotic-Resistant Enteric Infections
Lewis, B. B., & Pamer, E. G. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090816-093549 · Cited by 50
Jiang, Z., Alexander, A., Shi, K., Valilis, E., Hu, S., Li, B., & DuPont, H. L. (2017) · Anaerobe · doi:10.1016/j.anaerobe.2017.08.003 · Cited by 50
Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection
Varier, R. U., Biltaji, E., Smith, K. J., Roberts, M. S., Jensen, M. K., Lafleur, J., & Nelson, R. E. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12805 · Cited by 49
Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans
Staley, C. M., Khoruts, A., & Sadowsky, M. J. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.11.006 · Cited by 50
Fecal microbiota transplantation (FMT) for C. difficile infection, just say ‘No’
Tan, X., & Johnson, S. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102092 · Cited by 49
Broecker, F., Klumpp, J., & Moelling, K. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13100 · Cited by 48
Faecal microbiota transplantation: establishment of a clinical application framework
Jørgensen, S. M. D., Hansen, M. M., Erikstrup, C., Dahlerup, J. F., & Hvas, C. L. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000958 · Cited by 47
Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead
Borody, T. J., Fischer, M., Mitchell, S., & Campbell, J. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1086267 · Cited by 47
Adverse events of fecal microbiota transplantation: a metaanalysis of high-quality studies
Michailidis, L., Currier, A. C., Le, M., & Flomenhoft, D. R. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0655 · Cited by 48
“FMT delivery methods included: colonoscopy [22,23], enema [17], nasoduodenal tube [9], capsules [52], and various methods in 4 of the studies [50,51,53,54].”
BackgroundMethodInfluentialKunishima, H., Ohge, H., Suzuki, H., Nakamura, A., Matsumoto, K., Mikamo, H., Mori, N., Morinaga, Y., Yanagihara, K., Yamagishi, Y., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.011 · Cited by 48
Curry, S. R. (2010) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2010.04.001 · Cited by 47
Drekonja, D. M., Shaukat, A., Huang, Y., Zhang, J. H., Reinink, A. R., Nugent, S. M., Dominitz, J. A., Davis‐Karim, A., Gerding, D. N., & Kyriakides, T. C. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae467 · Cited by 48
Gut dysbiosis and metabolic diseases
Bandopadhyay, P., & Ganguly, D. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.06.031 · Cited by 46
Fecal Microbiota Transplantation in Liver Cirrhosis
Boicean, A., Bîrluțiu, V., Ichim, C., Brusnic, O., & Onișor, D. M. (2023) · Biomedicines · doi:10.3390/biomedicines11112930 · Cited by 45
Predictors of fecal transplant failure
Meighani, A., Hart, B. R., Mittal, C., Miller, N., John, A., & Ramesh, M. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000614 · Cited by 39
Baunwall, S. M. D., Dahlerup, J. F., Engberg, J., Erikstrup, C., Helms, M., Juel, M. A., Kjeldsen, J., Nielsen, H. L., Nilsson, A. C., Rode, A. A., et al. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1922749 · Cited by 45
Crow, J. R., Davis, S. L., Chaykosky, D., Smith, T. T., & Smith, J. M. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1644 · Cited by 45
Sun, D., Li, W., Li, S., Cen, Y., Xu, Q., Li, Y., Sun, Y., Qi, Y., Lin, Y., Yang, T., et al. (2016) · Medicine · doi:10.1097/md.0000000000003765 · Cited by 44
Reigadas, E., Bouza, E., Olmedo, M., Vázquez‐Cuesta, S., Villar-Gómara, L., Alcalá, L., Marín, M., Fernández, S. R., Valerio, M., & Muñóz, P. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.12.022 · Cited by 44
Kurt, F., Leventhal, G. E., Spalinger, M. R., Anthamatten, L., von Bieberstein, P. R., Menzi, C., Reichlin, M., Meola, M., Rosenthal, F., Rogler, G., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2177486 · Cited by 44
“Glycerol was added to reach a final concentration of 10% (as specified by Youngster et al.68).”
MethodClostridioides difficile Infection
Stewart, D. B. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1701228 · Cited by 43
Current and future applications of fecal microbiota transplantation for children
Chen, C.-C., & Chiu, C. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.11.004 · Cited by 43
“[62] Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al.”
BackgroundGuidelines for Clostridium difficile infection in adults
Kukla, M., Adrych, K., Dobrowolska, A., Mach, T., Reguła, J., & Rydzewska, G. M. (2020) · Gastroenterology Review · doi:10.5114/pg.2020.93629 · Cited by 42
“The effectiveness of FMT is still subject to research, and the effectiveness of FMT was lower in magnitude in randomised controlled trials compared to non-randomised studies [68, 69].”
ResultFecal microbiota transplantation for recurrent Clostridioides difficile , safety, and pitfalls
Sandhu, A., & Chopra, T. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211053105 · Cited by 41
Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea
Gweon, T., Lee, Y. J., Kim, K. O., Yim, S. K., Soh, J. S., Kim, S. Y., Park, J. J., Shin, S. Y., Lee, T. H., Choi, C. H., et al. (2022) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm21221 · Cited by 42
“The most common followup period of primary outcome in CDI studies was about 2 months.(51,64,97,98) The studies defined the primary endpoint as clinical resolution and/or absence of CDI recurrence.”
BackgroundTreatment of Recurrent and Severe Clostridium Difficile Infection
Keller, J. J., & Kuijper, E. J. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-070813-114317 · Cited by 35
Robust and Scalable Models of Microbiome DynamicsPreprint
Gibson, T. E., & Gerber, G. K. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1805.04591 · Cited by 41
“There is strong evidence that the microbiome plays an important role in a variety of human diseases, including: infections, arthritis, food allergy, cancer, inflammatory bowel disease, neurological diseases, and obesity/diabetes [10, 25, 21, 20, 14, 24].”
BackgroundHuman intestinal microbiome: Role in health and disease
Cantón, R., Ramos, P. D. L., Botella, A. G., García‐Lledó, A., Hernández‐Sampelayo, T., Gómez‐Pavón, J., del Castillo, J. M. G., Martín-Delgado, M. C., Martín‐Sánchez, F. J., Martínez‐Sellés, M., et al. (2024) · Revista Española de Quimioterapia · doi:10.37201/req/056.2024 · Cited by 40
Faecal microbiota transplantation: a regulatory hurdle?
Verbeke, F., Janssens, Y., Wynendaele, E., & Spiegeleer, B. D. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0687-5 · Cited by 40
“concluded that the route of administration appears to yield comparable diarrhea resolution without relapses up to 8 weeks post-transplantation and improved self-reported health scores with an overall cure rate of 90% [39].”
BackgroundAlrabaa, S. F., Jariwala, R., Zeitler, K. E., & Montero, J. (2017) · Transplant Infectious Disease · doi:10.1111/tid.12726 · Cited by 39
Shen, Z., Zhu, C., Quan, Y., Yuan, W., Wu, S., Yang, Z., Luo, W., Tan, B., & Wang, X. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13861 · Cited by 39
The intestinal microbiome and surgical disease
Krezalek, M. A., Skowron, K. B., Guyton, K. L., Shakhsheer, B. A., Hyoju, S. K., & Alverdy, J. C. (2016) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2016.06.001 · Cited by 39
Recurrent Clostridium difficile infection and the microbiome
Almeida, R., Gerbaba, T. K., & Petrof, E. O. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1099-3 · Cited by 38
“inoculum from unrelated donors resulted in clinical resolution in 70 % of cases after a single treatment, which increased to 90 % with retreatment [72].”
Use of probiotics in prevention and treatment of patients with Clostridium difficile infection
Ollech, J. E., Shen, N. T., Crawford, C. V., & Ringel, Y. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.01.002 · Cited by 38
The Route to Palatable Fecal Microbiota Transplantation
Fadda, H. M. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-1637-z · Cited by 37
“A dose-dependent response has been reported in other studies (59,68), and a minimum dose has been proposed to be necessary for FMT success (42).”
BackgroundResultColonic transendoscopic tube-delivered enteral therapy (with video): a prospective study
Zhang, T., Long, C., Cui, B., Buch, H., Wen, Q., Li, Q., Ding, X., Ji, G., & Zhang, F. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01285-0 · Cited by 37
The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection
Goldenberg, S. D., & Merrick, B. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936120981526 · Cited by 36
Żebrowska-Różańska, P., Łaczmańska, I., & Łaczmański, Ł. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.630052 · Cited by 36
Curry, S. R. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.01.007 · Cited by 36
The practice of fecal microbiota transplantation in inflammatory bowel disease
Arora, U., Kedia, S., & Ahuja, V. (2023) · Intestinal Research · doi:10.5217/ir.2023.00085 · Cited by 35
Bednárik, D. S., Földvári-Nagy, K. C., Simon, V., Rancz, A., Gede, N., Veres, D. S., Paraskevopoulos, P., Schnabel, T., Erőss, B. M., Hegyi, P., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101151 · Cited by 35
Fecal Microbiota Transplantation and Its Potential Therapeutic Uses in Gastrointestinal Disorders
Heath, R. D., Cockerell, C., Mankoo, R., Ibdah, J. A., & Tahan, V. (2017) · Northern Clinics of Istanbul · doi:10.14744/nci.2017.10692 · Cited by 36
“, 2014 [28] RCT Oral capsule 20 70% resolution of symptoms”
BackgroundRevealing Complex Ecological Dynamics via Symbolic Regression
Chen, Y., Angulo, M. T., & Liu, Y. (2019) · BioEssays · doi:10.1002/bies.201900069 · Cited by 35
“Yet, despite the growing importance of research on those complex ecosystems, there is a remarkable lack of mechanistic understanding of their dynamic behavior.”
BackgroundHeimesaat, M. M., Mrazek, K., & Bereswill, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02272 · Cited by 35
Kassam, Z., Lee, C., & Hunt, R. H. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.08.007 · Cited by 34
Han, S. S., Shannahan, S. E., & Pellish, R. S. (2016) · Journal of Intensive Care Medicine · doi:10.1177/0885066615594344 · Cited by 34
Faecal microbiota transplantation: from practice to legislation before considering industrialization
Lagier, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12795 · Cited by 34
“Since then, alternative methods using colonoscopy, duodenal tubes or nasogastric tubes have been established [28,31].”
BackgroundMethodDiagnosis and Management of Clostridium difficile Infection
Korman, T. M. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398741 · Cited by 34
Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders
Lee, H. J., Choi, J., Ryu, H. S., Choi, C. H., Kang, E. H., Park, K. S., Min, Y. W., & Hong, K. S. (2017) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16124 · Cited by 35
Cammarota, G., Pecere, S., Ianiro, G., Masucci, L., & Currò, D. (2016) · Digestive Diseases · doi:10.1159/000443362 · Cited by 30
Investigational new treatments for Clostridium difficile infection
Ivarsson, M. E., Leroux, J., & Castagner, B. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.003 · Cited by 33
Controlling the human microbiome
Liu, Y. (2023) · Cell Systems · doi:10.1016/j.cels.2022.12.010 · Cited by 32
Kappéter, Á., Sipos, D., Varga, A., Vigvári, S., Halda-Kiss, B., & Péterfi, Z. (2023) · Microorganisms · doi:10.3390/microorganisms11082083 · Cited by 32
“Based on a recent observational study by Péterfi and his team, it has been shown that the use of bacteria-free stool preparation in capsules is as effective as full-stool transplants [77,78,81,82] for the treatment of CDI.”
BackgroundClinical review of Clostridium difficile infection: an update on treatment and prevention
Daniels, L. M., & Kufel, W. D. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1524872 · Cited by 32
Stallmach, A., Steube, A., Grunert, P., Hartmann, M., Biehl, L. M., & Vehreschild, M. J. G. T. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0031 · Cited by 32
Juul, F. E., Bretthauer, M., Johnsen, P. H., Samy, F., Tonby, K., Berdal, J., Hoff, D. A. L., Ofstad, E. H., Abraham, A., Seip, B., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03285 · Cited by 30
Metadata
- Authors
- Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Corresponding author
- Youngster, Ilan
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-23
- Volume
- 58
- Issue
- 11
- Pages
- 1515-1522
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC4017893
- OpenAlex
- W2146116383
- Cited by
- 467
- References
- 32
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 31 · 2023: 22 · 2022: 24 · 2021: 35 · 2020: 37 · 2019: 51 · 2018: 47 · 2017: 57 · 2016: 53 · 2015: 61 · 2014: 27
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000170)
- National Institute of Allergy and Infectious Diseases (HHSN272200900018C)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, unrelated donor, nasogastric tube administration, diarrhea resolution, health-related quality of life, antibiotic-refractory infection
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Biological Therapy, Child, Clostridium Infections, Colonoscopy, Diarrhea, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Pilot Projects, Surveys and Questionnaires, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Unrelated Donors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.